col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


51 Results       Page 1

 [1] 
Elsevier: Cytokine & Growth Factor Reviews
  original article Date Title Authors   All Authors
1 [GO] 2022―Oct―13 Pharmacological therapies and drug development targeting SARS-CoV-2 infection Yizhou Jiang, Limor Rubin, Zhiwei Zhou, Haibo Zhang, Qiaozhu Su, Sheng-Tao Hou, et al. (+2)
2 [GO] 2022―Jul―07 Clinical progress in MSC-based therapies for the management of severe COVID-19 Maria Rossello-Gelabert, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez
3 [GO] 2022―Feb―12 The Coronavirus Pandemic - 2022: Viruses, Variants & Vaccines Magdalini Alexandridi, Julija Mazej, Enrico Palermo, John Hiscott
4 [GO] 2022―Jan―31 Roles of the Gut Microbiota in Severe SARS-CoV-2 Infection Yiran Liu, Dan Kuang, Dan Li, Ju Yang, Jiai Yan, Yanping Xia, et al. (+2)
5 [GO] 2022―Jan―13 Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review Ling-Ying Lu, Po-Hao Feng, Ming-Sun Yu, Min-Chi Chen, Alex Jia-Hong Lin, Justin L. Chen, Lennex Hsueh-Lin Yu
6 [GO] 2022―Jan―08 Before the “cytokine storm”: boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications Somit Dutta, Amartya Mukherjee, Upendra Nongthomba
7 [GO] 2021―Dec―16 EXPLOITING NATURAL ANTIVIRAL IMMUNITY FOR THE CONTROL OF PANDEMICS: LESSONS FROM COVID-19 Eleonora Aricò, Laura Bracci, Luciano Castiello, Francesca Urbani, Jean-Laurent Casanova, Filippo Belardelli
8 [GO] 2021―Nov―15 SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities Mohammad Shah Alam, Daniel M. Czajkowsky
9 [GO] 2021―Oct―25 Cancer and Covid-19: Collectively Catastrophic M du Plessis, C Fourie, J Riedemann, WJS de Villiers, AM Engelbrecht
10 [GO] 2021―Oct―25 Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism Firdos Ahmad, Meganathan Kannan, Abdul W. Ansari
11 [GO] 2021―Oct―22 COVID-19 and dys-regulation of pulmonary endothelium: implications of vascular remodeling Pavitra K. Jadaun, Suvro Chatterjee
12 [GO] 2021―Oct―19 S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes Leah Mellett, Shabaana A. Khader
13 [GO] 2021―Aug―02 ORF8a as a viroporin in SARS-CoV-2 infection? Milad Zandi
14 [GO] 2021―Jul―02 THE MOST RECENT SARS-CoV-2 MUTATIONS AND THEIR SUBSEQUENT VIRAL VARIANTS Begum Cosar, Zeynep Yagmur Karagulleoglu, Sinan Unal, Ahmet Turan Ince, Dilruba Beyza Uncuoglu, Gizem Tuncer, et al. (+16)
15 [GO] 2021―Jun―18 The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies Ni Zhao, Bin Di, Li-li Xu
16 [GO] 2021―Apr―15 COVID-19 as a Mediator of Interferon Deficiency and Hyperinflammation: Rationale for the Use of JAK1/2 Inhibitors in Combination with Interferon H.C. Hasselbalch, V. Skov, L. Kjær, C. Ellervik, A. Poulsen, T.D. Poulsen, C.H. Nielsen
17 [GO] 2021―Feb―21 SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders Amruta Narayanappa, Wesley H. Chastain, Meshi Paz, Rebecca J. Solch, Isabel C. Murray-Brown, Jaime B. Befeler, et al. (+4)
18 [GO] 2021―Feb―10 Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors Jorge Quarleri, M. Victoria Delpino
19 [GO] 2021―Jan―29 Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity Ghislain Opdenakker, Jo Van Damme
20 [GO] 2021―Jan―12 The Cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved Francesca Coperchini, Luca Chiovato, Gianluca Ricci, Laura Croce, Flavia Magri, Mario Rotondi
21 [GO] 2020―Dec―16 Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy Inês Barros, António Silva, Luís Pereira de Almeida, Catarina Oliveira Miranda
22 [GO] 2020―Dec―13 The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy Jing Li, Bin Liu
23 [GO] 2020―Dec―01 SARS-CoV-2: targeted managements and vaccine development Moiz Bakhiet, Sebastien Taurin
24 [GO] 2020―Nov―05 Covid-19 in Brazil: A sad scenario Pedro Rafael D. Marinho, Gauss M. Cordeiro, Hemílio F.C. Coelho, Simone Cristina S. Brandão
25 [GO] 2020―Nov―04 Oncolytic Viral Immunotherapy in the Time of COVID-19 David Olagnier, Tommy Alain
26 [GO] 2020―Oct―23 A Clinical Trial of IL-15 and IL-21 Combination Therapy For COVID-19 Is Warranted Stephen W. Wilz
27 [GO] 2020―Oct―09 Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19 Hamed Fouladseresht, Mehrnoosh Doroudchi, Najmeh Rokhtabnak, Hossein Abdolrahimzadehfard, Amir Roudgari, Golnar Sabetian, Shahram Paydar
28 [GO] 2020―Oct―08 Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19 Lucia Gabriele, Alessandra Fragale, Giulia Romagnoli, Stefania Parlato, Caterina Lapenta, Stefano Maria Santini, et al. (+2)
29 [GO] 2020―Sep―21 Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Simone Cristina Soares Brandão, Júlia de Oliveira Xavier Ramos, Luca Terracini Dompieri, Emmanuelle Tenório Albuquerque Madruga Godoi, José Luiz Figueiredo, Emanuel Sávio Cavalcanti Sarinho, et al. (+2)
30 [GO] 2020―Sep―09 AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm Sebastiano Gangemi, Alessandro Tonacci
31 [GO] 2020―Aug―25 Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19 Zhigang Hu, Sijia Li, Xinyu Song
32 [GO] 2020―Aug―25 Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic Anil Kumar Rana, Shubham Nilkanth Rahmatkar, Amit Kumar, Damanpreet Singh
33 [GO] 2020―Jul―18 Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella Francesco Prattichizzo, Massimiliano Bonafè, Angelica Giuliani, Andrea Costantini, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri
34 [GO] 2020―Jul―04 Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? Eleonora Aricò, Laura Bracci, Luciano Castiello, Sandra Gessani, Filippo Belardelli
35 [GO] 2020―Jul―01 Cytokine Storm in COVID-19 patients transforms to a Cytokine Super Cyclone in patients with risk factors Betcy Susan Johnson, Malini Laloraya
36 [GO] 2020―Jun―24 A critical evaluation of glucocorticoids in the treatment of severe COVID-19 Cinzia Solinas, Laura Perra, Marco Aiello, Edoardo Migliori, Nicola Petrosillo
37 [GO] 2020―Jun―20 Overview of the COVID-19 and JAK/STAT Pathway Inhibition: Ruxolitinib Perspective Bakiye Goker Bagca, Cigir Biray Avci
38 [GO] 2020―Jun―11 Should we unstress SARS-CoV-2 infected cells? Fabiana Csukasi, Gustavo Rico, Jose Becerra, Ivan Duran
39 [GO] 2020―Jun―07 COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu? Mohamed A. Eldeeb, Faraz S. Hussain, Zaeem A. Siddiqi
40 [GO] 2020―Jun―06 IL-15 immunotherapy is a viable strategy for COVID-19 Hemanth Kumar Kandikattu, Sathisha Upparahalli Venkateshaiah, Sandeep Kumar, Anil Mishra
41 [GO] 2020―Jun―04 Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” Eugenia Quiros-Roldan, Giorgio Biasiotto, Isabella Zanella
42 [GO] 2020―Jun―02 SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Víctor J. Costela-Ruiz, Rebeca Illescas-Montes, Jose M. Puerta-Puerta, Concepción Ruiz, Lucia Melguizo-Rodríguez
43 [GO] 2020―May―28 The global impact of the coronavirus pandemic John Hiscott, Magdalini Alexandridi, Michela Muscolini, Evelyne Tassone, Enrico Palermo, Maria Soultsioti, Alessandra Zevini
44 [GO] 2020―May―20 IL-6: relevance for immunopathology of SARS-CoV-2 E.O. Gubernatorova, E.A. Gorshkova, A.I. Polinova, M.D. Drutskaya
45 [GO] 2020―May―20 Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Cecilia T. Costiniuk, Mohammad-Ali Jenabian
46 [GO] 2020―May―13 The Covid-19 pandemic in Denmark: Big lessons from a small country David Olagnier, Trine H. Mogensen
47 [GO] 2020―May―11 The Cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Francesca Coperchini, Luca Chiovato, Laura Croce, Flavia Magri, Mario Rotondi
48 [GO] 2020―May―07 COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Shivraj Hariram Nile, Arti Nile, Jiayin Qiu, Lin Li, Xu Jia, Guoyin Kai
49 [GO] 2020―May―06 Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients Begum Dariya, Ganji Purnachandra Nagaraju
50 [GO] 2020―May―04 Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes Massimiliano Bonafè, Francesco Prattichizzo, Angelica Giuliani, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri
51 [GO] 2020―Apr―25 Cytokine storm intervention in the early stages of COVID-19 pneumonia Xinjuan Sun, Tianyuan Wang, Dayong Cai, Zhiwei Hu, Jin’an Chen, Hui Liao, et al. (+6)
 [1] 

51 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.006 sec